Abcam, ab185438, Cathepsin B Inhibitor Screening Kit (Fluorometric)

Size: 100Test
Abcam's Cathepsin B Inhibitor Screening Kit (ab185438) utilizes the ability of Cathepsin B to cleave the synthetic AFC based peptide substrate to release AFC, which can be easily quantified using a fluorometer or fluorescence microplate reader.
Key facts
Detection method:Fluorescent,
Sample types:Inhibitor compounds,
Assay type:Semi-quantitative,
Assay Platform:Microplate reader

Product details:
Abcam's Cathepsin B Inhibitor Screening Kit (ab185438) utilizes the ability of Cathepsin B to cleave the synthetic AFC based peptide substrate to release AFC, which can be easily quantified using a fluorometer or fluorescence microplate reader. In the presence of a Cathepsin B-specific inhibitor, the cleavage of the substrate is reduced/abolished resulting in decrease or total loss of the AFC fluorescence. This high-throughput adaptable assay kit is simple, sensitive, and rapid tool to screen the potential inhibitors of Cathepsin B.
Visit our
page for tips and troubleshooting.
This product is manufactured by BioVision, an Abcam company and was previously called K147 Cathepsin B (CTSB) Inhibitor Screening Kit (Fluorometric). K147-100 is the same size as the 100 test size of ab185438.
Cathepsin B (CTSB, EC 3.4.22.1) is a lysosomal cysteine proteinase that is suggested to participate in intracellular degradation and turnover of proteins. It has also been implicated in tumor invasion and metastasis.
The Safety Datasheet for this product has been updated for certain countries. Please check the current version in the Support and downloads section.

Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Cathepsin B also known as CTSB or cathepsin beta is a lysosomal cysteine protease belonging to the papain family. This enzyme possesses a molecular weight of approximately 25 to 30 kDa. You can find cathepsin B expressed in various tissues with high levels observed in the liver kidney and spleen. It plays a mechanical role in protein degradation within lysosomes operating optimally in acidic environments. The enzyme has active and inactive forms depending on structural modifications and environmental conditions.
Biological function summary
Cathepsin B participates as a proteolytic enzyme involved in protein turnover and processing. It does not function in isolation but often associates with various other proteases forming complexes essential for efficient substrate breakdown. Cathepsin B assists in the activation of other enzymes by cleaving propeptides therefore facilitating the initiation of cascade reactions. This role is critical in maintaining cellular homeostasis and modulating physiological processes including cell migration and immune response modulation.
Pathways
Cathepsin B significantly contributes to the lysosomal protein degradation pathway and the autophagy-lysosome pathway. It interacts with proteins such as B protein which are important for cellular recycling and energy homeostasis. Its activity supports the MHC class II antigen processing pathway playing an essential part in immune system functionality. Cathepsin B also exhibits interactions with Ctsb protein inhibitors which regulate its proteolytic activity within these pathways.
Cathepsin B has strong associations with cancer progression and neurological disorders such as Alzheimer's disease. Its overexpression and dysregulation are linked to tumor metastasis where it degrades extracellular matrix components promoting invasion. Ctsb protein interactions with corey mazo proteins influence tumor microenvironment and immune evasion. In Alzheimer's disease cathepsin B can influence amyloid beta peptide processing connected to neurodegenerative pathology progression. These roles highlight the potential for cathepsin B as a therapeutic target in addressing these conditions.